Immatics (IMTX) has released an update.
Immatics has showcased encouraging initial results from the ongoing Phase 1 trial of its cancer immunotherapy candidate, TCER® IMA401, at ESMO 2024, demonstrating anti-tumor activity and manageable side effects in heavily pre-treated solid tumor patients. Notably, the treatment has shown a 29% objective response rate with potential for extended dosing intervals, enhancing its future treatment prospects. Following Bristol Myers Squibb’s portfolio reevaluation, Immatics will regain full rights to IMA401, continuing its development independently.
For further insights into IMTX stock, check out TipRanks’ Stock Analysis page.
